Transition is a biopharmaceutical company that develops novel therapeutics for central nervous system and metabolic disease indications. Read more

128 Followers on Owler
128 Followers on Owler
128 Followers on Owler
128 Followers on Owler

Transition is a biopharmaceutical company that develops novel therapeutics for central nervous system and metabolic disease indications. Read more

Tony Cruz's photo - Co-Founder & CEO of Transition Therapeutics

Co-Founder & CEO

Tony Cruz

CEO Approval Rating

72/100

Est. Annual Revenue
Est. Employees
Sector

Update Industry

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Minerva Neurosciences is Transition Therapeutics's biggest rival. Minerva Neurosciences was founded in Waltham, Massachusetts} in 2007. Minerva Neurosciences operates in the Pharmaceuticals industry. Compared to Transition Therapeutics, Minerva Neurosciences generates $146.8M more revenue.

Acadia is Transition Therapeutics's #2 rival. Acadia's headquarters is in San Diego, California, and was founded in 1993. Acadia competes in the Biotechnology field. Acadia generates 2,336% of Transition Therapeutics's revenue.

Voyager is Transition Therapeutics's #3 competitor. Voyager was founded in 2014 in Cambridge, Massachusetts. Voyager operates in the Biotechnology industry. Voyager generates $167.1M more revenue than Transition Therapeutics.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 16 a good estimate for Transition Therapeutics's Employee count?

Acquisitions

No recent acquisitions found related to Transition Therapeutics

Transition Therapeutics Funding History

No recent funding data found related to Transition Therapeutics

Investments

No recent investments found related to Transition Therapeutics

Transition Therapeutics News

June 1, 2017BioPortfolio

Transition Therapeutics Inc TTH Pharmaceuticals Healthcare Deals and Alliances Profile Updated 17052017 Prices from USD $250

SummaryTransition Therapeutics Inc Transition is a biopharmaceutical company that develops medicines ... See more »
March 18, 2017BioPortfolio

Transition Therapeutics Inc TTH Pharmaceuticals Healthcare Deals and Alliances Profile Updated 24022017 Prices from USD $250

SummaryTransition Therapeutics Inc Transition is a biopharmaceutical company that develops medicines ... See more »
November 28, 2016BioPortfolio

Transition Therapeutics Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

SummaryMarketLine's Company Mergers Acquisitions MA Partnerships Alliances and Investments reports of... See more »
November 21, 2016BioPortfolio

Transition Therapeutics Inc. TTH Financial and Strategic SWOT Analysis Review Prices from USD $300

SummaryTransition Therapeutics Inc. Transition is a biopharmaceutical company that develops medicines... See more »
August 30, 2016The Business Journals

Phillip Frost's Opko Health completes $60M acquisition of biopharmaceutical firm

Opko Health announced Wednesday that it has completed its acquisition of Toronto-based biopharmaceuti... See more »
August 26, 2016BioPortfolio

Transition Therapeutics Shareholders Approve Acquisition by OPKO Health

Friday August 26th 2016 at 1252pm UTC MIAMI&8211;BUSINESS WIRE&8211; OPKO Health Inc. Nasdaq OPK anno... See more »
August 26, 2016Reuters

BRIEF-Transition Therapeutics Shareholders Approve Acquisition by OPKO Health

* Transition Therapeutics shareholders approve acquisition by OPKO Health... See more »

Transition Therapeutics Press Releases

March 22, 2016Business Wire

Down Syndrome Pipeline Review, H1 2016 Featuring AC Immune, Aelis Farma S.A.S., Eisai, F. Hoffmann-La Roche, NeuroNascent, & Transition Therapeutics - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3njltm/down... See more »
March 17, 2016PR Newswire

Transition Therapeutics Receives Notification From NASDAQ

TORONTO, March 17, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (... See more »
February 29, 2016PR Newswire

Transition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference

TORONTO, March 1, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (N... See more »
November 19, 2015PR NEWSWIRE

Transition Therapeutics to Host Investor Day November 23 in New York

Live Webcast Beginning at 12 PM Eastern Time TORONTO, Nov. 19, 2015 /PRNewswire/ - Transition Therape... See more »
November 11, 2015PR NEWSWIRE

Transition Therapeutics Announces First Quarter Fiscal 2016 Financial Results

TORONTO, Nov. 10, 2015 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (T... See more »
November 3, 2015BUSINESS WIRE

Global Down Syndrome Clinical Trials Review, H2, 2015

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9dn9rr/down... See more »
November 2, 2015CNW GROUP

Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2016 Financial Results on Tuesday, November 10th, at 4:30 P.M. EST

TORONTO, Nov. 2, 2015 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: T... See more »

Social Media

Headquarters

101 College Street Suite 220

Toronto, OntarioM5G 1L7

416-260-7770

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Transition is a biopharmaceutical company that develops novel therapeutics for central nervous system and metabolic disease indications. Transition Therapeutics was founded in 1998. Transition Therapeutics' headquarters is located in Toronto, Ontario,...

CEO

Transition Therapeutics's Co-Founder & CEO, Tony Cruz, currently has an approval rating of 72%. Transition Therapeutics's primary competitors are Minerva Neurosciences, Acadia & Voyager.

Website

transitiontherapeutics.com

Frequently Asked Questions about Transition Therapeutics

  1. When was Transition Therapeutics founded?

    Transition Therapeutics was founded in 1998
  2. Who is Transition Therapeutics's CEO?

    Transition Therapeutics's CEO is Tony Cruz
  3. How much revenue does Transition Therapeutics generate?

    Transition Therapeutics generates $17.9M in revenue
  4. How much funding does Transition Therapeutics have?

    Transition Therapeutics has historically raised $0 in funding
  1. Where is Transition Therapeutics's headquarters?

    Transition Therapeutics's headquarters is in Toronto Ontario, CA
  2. How many employees does Transition Therapeutics have?

    Transition Therapeutics has 16 employees
  3. Who are Transition Therapeutics's competitors?

    Transition Therapeutics's top competitors are Minerva Neurosciences, Acadia, Voyager